Amicus Brain Innovations Competitors

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

BrainCo’s leadership draws on deep experience in neuroscience research and expertise in education to deliver entirely new applications of brainwave technology in the education, wellness, and research spaces. We’ve learned important lessons as we’ve grown from a small team in an apartment basement to over 100 employees in 4 offices around the world. Since 2015 we’ve been working on providing the best experience possible for our customers and we’re here to share our progress and innovations with you.

Wave Neuroscience is a Newport Beach, California-based neurotechnology company founded in 2019 on a simple premise: mental health is brain health, and biomarker-guided neuromodulation can pioneer a new era in brain health treatment. Wave developed MeRT® (Magnetic e-Resonance Therapy), the first FDA-cleared personalized, EEG-guided neuromodulation system for PTSD. Unlike standard approaches cleared for other mental health conditions that apply the same protocol to every patient, MeRT begins with a quantitative EEG to map each patient’s unique brain activity, then delivers precisely derived transcranial magnetic stimulation (TMS) tailored to their individual neurophysiology. Wave's pivotal clinical trial demonstrated a 52% average reduction in PTSD symptoms — a superior outcome compared to antidepressants, trauma-focused talk therapy, and other FDA-cleared neuromodulation protocols. At the end of treatment, 68% of active participants classified as "in remission" by falling below the clinical threshold for PTSD.(1) Wave's mission is to move mental healthcare from subjective symptom management to measurable, personalized, effective intervention. (1) Pivotal Trial: Multi-site, double-blind, sham-controlled randomized trial (n=158). Primary endpoint: change in PTSD Checklist for DSM-5 (PCL-5) scores. All results favor active MeRT treatment group. Source: U.S. Food and Drug Administration. 510(k) Summary: MeRT® System (K260402). June 3, 2026.